Celecoxib Targeted Therapy Attenuates Mouse Colon Carcinogenesis through Modulation of Expression Patterns of Cancer Stem Cells

: Head and Neck Squamous Cell Carcinoma (HNSCC) is categorized as the sixth most common cancer worldwide, with an incidence of more than 830,000 cases per year and a mortality rate of 50%. Tobacco use, alcohol consumption, and Human Papillomavirus infection are the prominent risks for HNSCC. Despite significant developments in the treatment of HNSCC, a high rate of recurrences makes the clinical situation worse and results in poor survival rates. Recent perspectives demonstrate that whereas epithelial transformation plays a crucial role in cancer development, tumor surrounding microenvironment takes part in progression of cancer as well. Cancer Stem Cells (CSCs), which harbor unlimited self-renewal capacity, have a crucial role in the growth of HNSCC and this cell population is responsible for tumor recurrence unless eliminated by targeted therapy. CSCs are not only a promising target for tumor therapy, but also a crucial biomarker to determine the patients at high risk for undetermined results and disease development. Just as the bone marrow which is the niche of hematopoietic and mesenchymal stem cells, is important for stem cells maintenance. Similarly, the concept of microenvironment is also important for the maintenance of CSCs. Apart from the cell-cell interactions, there are many parameters in the cancer microenvironment that affect the development of cancer, such as extracellular regulation, vascularization, microbial flora, pH and oxygenation. The purpose of this review is to introduce HNSCC, explain the role of CSCs and their microenvironment and refer to the conventional and novel targeted therapy for HNSCC and CSCs.

Download Full-text

MicroRNA Targeted Therapy for Overcoming Drug Resistance, Reversal of EMT and Elimination of Cancer Stem Cells in Prostate and Pancreatic Cancer

MicroRNA Targeted Cancer Therapy ◽

10.1007/978-3-319-05134-5_12 ◽

2014 ◽

pp. 199-217 ◽

Cited By ~ 3

Author(s):

Yiwei Li ◽

Dejuan Kong ◽

Aamir Ahmad ◽

Bin Bao ◽

Fazlul H. Sarkar

Keyword(s):

Pancreatic Cancer ◽

Stem Cells ◽

Drug Resistance ◽

Targeted Therapy ◽

Cancer Stem Cells ◽

Resistance Reversal

Download Full-text

Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy

Urologia Internationalis ◽

10.1159/000455160 ◽

2017 ◽

Vol 99 (2) ◽

pp. 125-136 ◽

Cited By ~ 23

Author(s):

Ricardo Leão ◽

Célia Domingos ◽

Arnaldo Figueiredo ◽

Robert Hamilton ◽

Uri Tabori ◽

...

Keyword(s):

Prostate Cancer ◽

Stem Cells ◽

Targeted Therapy ◽

Cancer Stem Cells

Download Full-text

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-16-1834 ◽

2016 ◽

Vol 23 (10) ◽

pp. 2516-2527 ◽

Cited By ~ 23

Author(s):

Samuel A. Kerk ◽

Kelsey A. Finkel ◽

Alexander T. Pearson ◽

Kristy A. Warner ◽

Zhaocheng Zhang ◽

...

Keyword(s):

Stem Cells ◽

Squamous Cell Carcinoma ◽

Targeted Therapy ◽

Cancer Stem Cells ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma

Download Full-text

Characterization of Gene Expression Patterns among Artificially Developed Cancer Stem Cells Using Spherical Self-Organizing Map

Cancer Informatics ◽

10.4137/cin.s39839 ◽

2016 ◽

Vol 15 ◽

pp. CIN.S39839 ◽

Cited By ~ 13

Author(s):

Akimasa Seno ◽

Tomonari Kasai ◽

Masashi Ikeda ◽

Arun Vaidyanath ◽

Junko Masuda ◽

...

Keyword(s):

Gene Expression ◽

Stem Cells ◽

Cancer Stem Cells ◽

Human Cancer ◽

Expression Patterns ◽

Embryonic Stem ◽

Culture Conditions ◽

Self Organizing Map ◽

Cancer Tissues ◽

Self Organizing

We performed gene expression microarray analysis coupled with spherical self-organizing map (sSOM) for artificially developed cancer stem cells (CSCs). The CSCs were developed from human induced pluripotent stem cells (hiPSCs) with the conditioned media of cancer cell lines, whereas the CSCs were induced from primary cell culture of human cancer tissues with defined factors ( OCT3/4, SOX2, and KLF4). These cells commonly expressed human embryonic stem cell (hESC)/hiPSC-specific genes ( POU5F1, SOX2, NANOG, LIN28, and SALL4) at a level equivalent to those of control hiPSC 201B7. The sSOM with unsupervised method demonstrated that the CSCs could be divided into three groups based on their culture conditions and original cancer tissues. Furthermore, with supervised method, sSOM nominated TMED9, RNASE1, NGFR, ST3GAL1, TNS4, BTG2, SLC16A3, CD177, CES1, GDF15, STMN2, FAM20A, NPPB, CD99, MYL7, PRSS23, AHNAK, and LOC152573 genes commonly upregulating among the CSCs compared to hiPSC, suggesting the gene signature of the CSCs.

Download Full-text

Targeting Breast Cancer Stem Cells (BCSCs) with Liposomal Formulations

Clinical Cancer Drugs ◽

10.2174/2212697x06666190318150757 ◽

2019 ◽

Vol 6 (1) ◽

pp. 3-7

Author(s):

Sumayah Al-Mahmood

Keyword(s):

Breast Cancer ◽

Stem Cells ◽

Multidrug Resistance ◽

Targeted Therapy ◽

Cancer Stem Cells ◽

Cancer Cells ◽

Breast Cancer Treatment ◽

Breast Cancer Stem Cells ◽

Liposomal Formulations ◽

Cancer Targeted Therapy

Breast cancer stem cells (BCSCs) are a small proportion of cells that may be responsible for improving the resistance of cancer cells to the treatment and metastasis of breast cancer (MBC). Nanovehicles such as liposomes are extensively explored for diagnosis, treatment, and imaging of cancer. Targeted therapy with nanoparticles can be used to overcome the chemoresistance problem of cancer stem cells. Liposomes are lipid bilayer nanocarriers that have the ability to inhibit Pglycoprotein to overcome multidrug resistance that makes liposome ideal choice for using in BCSCs therapy. The main objective of this review is to describe novel liposomal formulations that are used in targeting BCSCs, which help in improving breast cancer treatment.

Download Full-text

Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.7029 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 7029-7029 ◽

Cited By ~ 13

Author(s):

Arthur E. Frankel ◽

Marina Konopleva ◽

Donna Hogge ◽

David Rizzieri ◽

Christopher Brooks ◽

...

Keyword(s):

Stem Cells ◽

Targeted Therapy ◽

Cancer Stem Cells ◽

Single Agent ◽

Hematologic Malignancies ◽

Single Cycle ◽

Long Term Outcome ◽

Interleukin 3 ◽

Wide Range ◽

Refractory Aml

7029^ Background: SL-401 is a novel biologic targeted therapy directed to the interleukin-3 receptor (IL-3R). IL-3R is overexpressed on cancer stem cells (CSCs) and tumor bulk relative to normal hematopoietic cells in a wide range of hematologic malignancies including AML and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since SL-401 targets both leukemia blasts and CSCs, tumor regression and improvement in long-term outcome is expected. The clinical activity and side effect profile of SL-401 were evaluated in a multicenter Phase I/II trial of patients with advanced hematologic cancers. Methods: Eighty-one patients with advanced hematologic cancers, including relapsed or refractory AML (n = 59) and heavily pretreated BPDCN (n = 4), have been enrolled. Patients received a single cycle of SL-401 via 15-minute IV infusion to determine the maximum tolerated dose (MTD) and assess antitumor activity. Results: A single cycle of SL-401 demonstrated single agent activity in relapsed or refractory AML patients, including 2 durable CRs of 8 and 25+ months duration and multiple cases of blast reductions. SL-401, when delivered at therapeutically relevant doses, was associated with > 3-fold greater median overall survival (OS) in AML patients who received 2+ prior lines of treatment relative to historical results. In addition, 3 heavily pre-treated patients with BPDCN, an uncommon malignancy that expresses high levels of IL-3R and is ultrasensitive to SL-401 (IC50 values in the femtomolar [10-15 M] range), had CRs, with durations of 5, 3+ and 1+ months. The MTD was 16.6 µg/kg/day; the dose-limiting toxicities of hypoalbuminemia and edema, which are manifestations of capillary leak, occurred at 22.1 µg/kg/day. Other ≥ Grade 3 adverse events included transient transaminase elevations. There was no treatment-related myelosuppression. Conclusions: SL-401 was well tolerated and demonstrated single agent activity in patients with relapsed or refractory AML and BPDCN. Based on these findings, single agent SL-401 given in multiple cycles will be advanced into pivotal studies of AML (3rd-line) and BPDCN. Clinical trial information: NCT00397579.

Download Full-text